|Bid||8.59 x 1300|
|Ask||8.59 x 800|
|Day's Range||8.32 - 8.77|
|52 Week Range||1.80 - 12.44|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the Company as Senior Vice President and Chief Financial Officer on March 1, 2021, the Company granted her a non-statutory stock option to purchase 350,000 shares of Dynavax common stock. In addition, it also granted nonstatutory stock options to purchase an aggregate of 74,300 shares of Dynavax common stock as inducements to four newly-hired employees in connection with commencement of their employment with the Company.
Shares of Dynavax Technologies (NASDAQ: DVAX) were soaring 18.8% as of 10:50 a.m. EST on Friday. The big gain came after the company announced better-than-expected fourth-quarter results after the market close on Thursday. Dynavax expects to make between $40 million and $60 million in the first quarter of this year from its CpG 1018 vaccine adjuvant.